Accessibility Menu
PureTech Health Plc logo

PureTech Health Plc(LSE) PRTC

Market Cap£294.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-32%
5 Year-65%
1 Year+4%
1 Month+5%
£1.20
+0.00%
+0.00Today
PureTech Health Plc last closing stock price
MetricPriceDate
Last closeGBX 120.802026-09-02
PureTech Health Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.33%GBX 120.402026-08-26
1 month+4.68%GBX 115.402026-08-03
3 month-4.58%GBX 126.602026-06-04
Year to date-3.36%GBX 125.002025-12-31
1 year+4.14%GBX 116.002025-09-02
3 year-39.6%GBX 200.002023-09-01
5 year-65.09%GBX 346.002021-09-03
Since inception-32.36%GBX 1.782015-06-19

PureTech Health Plc Financials at a Glance

Market Cap

£294.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.99M

Net Income (TTM)

-$56.54M

EPS (TTM)

-£0.34

P/E Ratio

-3.49

Dividend

£0.00

Beta (Volatility)

-0.07 (Low)

Price

£1.20

Volume

345,176

Open

£1.25

Previous Close

£1.20

Daily Range

£1.19 - £1.25

52-Week Range

£1.05 - £1.43

Estimated Earnings Date

Sep 3, 2026

PRTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PureTech Health Plc

PureTech Health plc is a biotechnology company focused on developing differentiated medicines for serious diseases, including inflammatory, fibrotic, and immunological conditions. The company operates through various segments, including Internal, Controlled Founded Entities, and Non-Controlled Founded Entities, aiming to address unmet medical needs.

Products and Services
  • Innovative therapies for inflammatory and fibrotic diseases
  • Targeted treatments for intractable cancers
  • Advanced solutions for neurological disorders
Growth Outlook
  • Recent revenue growth of 52% year-over-year in Q4 2024
  • Strong pipeline with multiple candidates in clinical trials
  • Strategic partnerships enhancing research and development capabilities
Financial Highlights
  • Q4 2025 revenue of $2.82 million, up from $1.85 million in Q2 2025
  • Net income for Q4 2025 improved to -$65.4 million from -$44.6 million in Q2 2025
  • Cash and short-term investments totaled $278.99 million as of Q4 2025
PureTech Health plc is positioned in the biotechnology sector, focusing on innovative solutions for complex health challenges. The company's diverse product offerings and strategic focus on research and development provide a solid foundation for future growth. Recent financial performance indicates a positive trend, with significant revenue increases and a robust cash position, which may attract potential investors looking for opportunities in the healthcare industry. The ongoing development of its product pipeline and strategic partnerships further enhance its potential for long-term success.
AI Generated • Aug 19, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Robert William Henry Lyne

Website

puretechhealth.com

Headquarters

Boston, MA 02210, US

PRTC Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-29.49%

Return on Capital

-30.30%

Return on Assets

N/A

Earnings Yield

-28.65%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

£294.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

244.38M

Volume

345.18K

Avg. Volume

616.43K

Financials (TTM)

Gross Profit

-$17.58M

Operating Income

-$234.86M

EBITDA

-$58.03M

Operating Cash Flow

-$218.18M

Capital Expenditure

-$17.03K

Free Cash Flow

-$218.20M

Cash & ST Invst.

$279.00M

Total Debt

$19.76M

PureTech Health Plc Performance Analysis

PureTech Health Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 12,679,2100.3%
20232023-12-31USD 2,678,891-78.9%
20242024-12-31USD 3,778,33341.0%
20252025-12-31USD 3,535,196-6.4%
PureTech Health Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3060.0%
Q42024-12-311298.3%
Q22025-06-30-54.0%
Q42025-12-3152.4%
PureTech Health Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.14-6.5%
20232023-12-31USD -0.1933.2%
20242024-12-31USD 0.16N/A
20252025-12-31USD -0.35N/A
PureTech Health Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31333.3%
Q22025-06-30-154.3%
Q42025-12-31-42.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$2.82M

+1467.5%

Gross Profit

$1.16M

+102.7%

Gross Margin

41.03%

N/A

Market Cap

£294.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£5.25M

N/A

Employees

56

N/A

Net Income

-$65.45M

-60.8%

EBITDA

-$49.17M

+28.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$279.00M

-14.7%

Total Debt

$19.76M

-85.4%

Accounts Receivable

$8.13M

+242.3%

Inventory

$0.00

-100.0%

Long Term Debt

$11.09M

-91.4%

Short Term Debt

$8.50M

+19.8%

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$37.87M

+7.1%

Operating Cash Flow

-$37.87M

+7.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NIOX.LNIOX Group Plc
£0.68-0.59%
BXP.LBeximco Pharmaceuticals Limited
£0.63+13.64%
AVCT.LAvacta Group Plc
£0.67-1.47%
AGY.LAllergy Therapeutics plc
£0.05-3.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$224.41+0.03%
PCGPG&E
$13.33-0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.37+0.00%
NUNu Holdings
$15.40+0.07%

Questions About PRTC

What is the current price of PureTech Health Plc?

PureTech Health Plc is trading at £1.20 per share.

What is the 52-week range for PureTech Health Plc?

Over the past 52 weeks, PureTech Health Plc has traded between £1.05 and £1.43.

How much debt does PureTech Health Plc have?

As of the most recent reporting period, PureTech Health Plc reported total debt of $14.69M.

How much cash does PureTech Health Plc have on hand?

PureTech Health Plc reported $188.89M in cash and cash equivalents in its most recent financial results.

What is PureTech Health Plc’s dividend yield?

PureTech Health Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services